The continuous instillation of plasmin (Thrombolysin) directly into the main pulmonary artery of greyhounds, using one half of the systemic doses, was found to be more effective in accelerating or enhancing in vivo lysis of artificially produced pulmonary emboli than systemic intravenous infusion. Animals which received direct pulmonary arterial instillations of Thrombolysin showed remarkably few macroemboli. By light microscopy, these clots showed zones of lysis mainly in the central portions of the clots. We suggest that the flow-guided catheterization of the main pulmonary artery used in this study on greyhounds can be applied to critically ill human subjects, as shown by earlier studies (Magtira, Winkler, Duprey, and Baum, 1966) . Continuous infusions of thrombolytic agents directly into the main pulmonary artery might then offer an effective therapy for human pulmonary embolism, especially during that critical period following a massive or sUbmassive embolic episode.
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Despite heparin anticoagulation and the continued refinements of surgical intervention, acute thromboembolism remains a frequent and distressing cause of morbidity and mortality in populations of the Western world, particularly in the middle-aged and the elderly. Pulmonary embolism is common and remains a challenge: it is one of the common causes of death in hospital, has been estimated to cause 47,000 deaths per year in the United States of America, and is the third most common cause of death at the Peter Bent Brigham Hospital (Dalen and Dexter, 1967 Until more is known about the exact pathogenesis of pulmonary embolism, thrombolytic agents may prove the best way to treat this disorder. Numerous substances have been employed in the past with the purpose of enhancing or supplementing in vivo fibrinolysis, but so far there has been inadequate information about these thrombolytic agents.
Here we have studied direct continuous instillation of a fibrinolytic agent into the main pulmonary artery in enhancing or accelerating clot lysis in vivo in greyhounds with artificially induced pulmonary embolism.
MATERIALS AND METHODS
Thrombolysin2 was used in this study. This compound is a streptokinase-activated human plasminogen preparation. It exhibits both profibrinolysinactivator and fibrinolytic properties, although its lytic properties have been attributed mainly to its streptokinase content. Fragmentation of the introduced macroemboli probably occurred prior to entry into smaller pulmonary arteries and probably occurred in the right heart as suggested by previous studies (Wessler, Freiman, Ballon, Katz, Wolff, and Wolf, 1961 Opacification of the pulmonary arteries was obtained by selective pulmonary arteriography using 35 ml. of AngioConray4 delivered through the flowguided catheter by power injection (pressure 110 lb./ sq. in.). Angiogram films were obtained using the Schonander rapid film changer. Pulmonary angiograms were obtained in the control period, after embolization, and after 'therapy'. The E.C.G. (limb lead II), mean pulmonary artery and systemic arterial pressures were continuously monitored and appropriately recorded. Serial studies also included arterial blood gas tensions (Po2 and Pco2) and pHs using the IL Ultra-Micro pH and Blood Gas Analysing System,5 cardiac outputs by a standard dye dilution method, and pulmonary vascular resistances (Motley, 1966) .
All animals were then sacrificed and immediately necropsied. The lungs were evaluated pathologically.
RESULTS
The pulmonary angiogram films shown in Fig. 1 represent typical findings from each of the three groups of animals. The 'after embolism' and '4th hour' films were similar as regards the visible pulmonary arterial filling defects, which sometimes were more apparent on the '4th hour' films. These findings were similar to those of previous studies (Dalen, Mathur, Evans, Haynes, Pur-Shahriari, Stein, and Dexter, 1966) . Similarly, in group 2 dogs there were persistent pulmonary arterial filling defects, sometimes more apparent on the '4th hour' films. In contrast, in group 3 dogs the previously appreciable intra-arterial filling defects were significantly decreased on the '4th hour' films. The findings are seen more clearly in Figure  2 . Areas of oligaemia are seen on all '4th hour' films, and are more appreciable on the '4th hour' angiogram films of group 3 animals. It is possible that group 3 dogs had more enhanced clot lysis with earlier fragmentation of macroemboli which probably lodged in arteries smaller than second order (diameter 0-1 to 10 mm.) as shown by previous studies (Dalen et al., 1966) .
Significant dilatation of the main pulmonary artery and its right and left branches was observed on all 'after embolism' angiograms, and was associated always with significant pulmonary hypertension. The same findings have been reported previously (Lochhead, Roberts, and Dotter, 1952) . We attempted to measure this dilatation by selecting on comparable angiograms a 10 sq. in. circular area with a fixed mid-reference point (Fig. 3) (Fig. 4) . The '4th hour' angiogram films of group 3 dogs had the least evidence of vascular dilatation. Some dogs in this group had areas actually smaller than their respective control values. This could possibly represent vasoconstriction due to miliary embolism (by microemboli, 8 to 100 ,u in diameter) following earlier fragmentation of rapidly lysing macroemboli, 0-17 to 4 mm. in diameter (Dalen, Haynes, Hoppin, Evans, Bhardwaj, and Dexter, 1967) . Is the reduction in the vascular areas a reflection of abnormalities secondary to a direct action of Thrombolysin on vascular walls ? Can the temporary presence of a clot cause injury to the vessel walls ? These are unanswered questions but still remain as justified speculations. The '4th hour' angiogram films of animals belonging to groups 1 and 2 showed similar findings-comparable and significant vascular dilatation. These two groups were clearly separable from group 3, as shown in Figure 4 .
Considering the pulmonary arterial hypertension (Fig. 5) , both intravenous and locally instilled Thrombolysin had significantly (P<0 001) beneficial effects (i.e., lowering of the pulmonary hypertension) when compared to locally instilled dextrose 5% in water solution. In addition, Thrombolysin directly instilled into the main pul- No clear-cut separation of the three groups of animals could be demonstrated with respect to cardiac outputs, pulmonary vascular resistances, and arterial blood gas tensions (Po2 and Pco2) and pHs. During and at the end of the fourth hour of study, the results of the arterial blood studies were similar in all animals. The P02 values ranged from 50 to 60 mm. Hg. The carbon dioxide tensions varied similarly in all dogs (35 to 40 mm. Hg). Arterial blood pHs ranged from 7-3 to 7N4. These degrees of hypoxaemia might have altered the pulmonary vascular resistance values. In the dog, hypoxaemia may cause an increase, a decrease, or no effect on calculated pulmonary vascular resistance. Using the dilution technique, the changes in resistance have ranged from -15 to +20% (Nahas, Visscher, Mather, Haddy, and Warner, 1954) . The anaesthesia could also have played a significant role in producing changes in cardiac output, regional blood distribution, and venous return (Scarborough, 1957) .
Heparin was not given just prior to sacrifice of the animals. Dogs belonging to'groups 2 and 3 were sacrificed while receiving the last few millilitres of the Thrombolysin solution. Previous studies (Back, Ambrus, Simpson, and Shulman, 1958) Clots seen were located mainly in the lower but occasionally in the upper lobes. The lungs of both group 1 and group 2 animals showed extensive macroembolization. Figure 6 shows an embolus (representative of macroemboli in these two groups of animals) which is intact with no evidence of lysis and resembles an intact in-vitro 'untreated' clot shown in Figure 7 . There were no abnormalities of the vascular walls seen by light microscopy.
In contrast. the lungs of animals in group 3 showed remarkably few macroemboli (involvement of only two to three vessels with fragile clots), with easily seen zones of lysis (Fig. 8) , most of which were located mainly in the central portions of the clots. These in-vivo findings resembled those seen in Thrombolysin-treated invitro clots (Fig. 9) . We are undertaking further histochemical studies (Kwaan and Astrup, 1965) .
DISCUSSION
Reliable evidence is still needed on the effectiveness of fibrinolytic therapy in pulmonary thromboembolism. The basic problem is probably due to the fact that, in the clinical situation, the fate of thrombi and emboli remains obscure.
There is a continuing search for effective thrombolytic agents and for the method of their administration. The studies of Courbier, Torresani, Monties, Patrice, Figarella, and Garabedian (1962) in dogs suggested that fibrinolysis improved the prognosis in pulmonary embolism and, in some animals, brought about complete resolution of pulmonary emboli. Previous studies (Hume, 1961) of several thrombolytic agents have shown unequivocal thrombolysis in several cases. Though effective thrombolytic agents may be at hand, available data concerning the target clot and the inhibitors of the thrombolytic system are still inadequate, and it is not really known why one clot will dissolve and another will not. Most recently, Hirsh, Hale, McDonald, McCarthy, and Cade (1967) reported two patients with acute massive pulmonary embolism who survived after pulmonary arterial infusion of streptokinase. These authors have amply emphasized the ideal treatment of pulmonary embolism: the removal of emboli as quickly and as safely as possible. This needs to be re-emphasized because, of the fatal cases of acute massive pulmonary embolism, the majority (about 50%) of patients succumb within the first hour following the embolic episode (Rosenberg, Pearce, and McNulty, 1964) , so that many patients die before an operation can be arranged.
Almost all patients with fatal pulmonary embolism have had previous episodes of embolism, and there is serious cardiac dysfunction when emboli occlude more than 60% of the pulmonary arterial bed. Most of these patients have mixed kinds of emboli older peripheral clots and relatively recent proximal ones. This latter type of clot probably forms following coating of relatively older clots by platelets. As the circulation becomes completely occluded, thrombi form through the red thrombus mechanism, resulting in the formation of the so-called propagating red tail (Deykin, 1967) . The initial place of thrombolytic therapy in the management of pulmonary embolism then would be to enhance in-vivo lysis of recent clots. Older emboli will probably require more prolonged, carefully monitored administration of thrombolytic agents.
No matter which theory is given preference to explain physiological in-vivo thrombolysis Ambrus and Markus, 1960; Norman, 1958; Sherry, Lindemeyer, Fletcher, and Alkjaersig, 1959) , the antiplasminplasmin-clot relationship provides the key to thrombolysis. The plasminogen content of the clot is probably important. The length of time that the clot is in contact with the circulation is equally of major importance.
Several requirements seem of utmost importance and must be satisfied for effective thrombolytic therapy: first, a susceptible clot where fibrin is the principal substrate; second, a susceptible clot containing significant amounts of trapped plasminogen; and, third, higher concentrations of active enzyme reaching the clot. Presumably, the enzyme will activate plasminogen on the surface of the clot with subsequent diffusion of active moieties into the clot leading to activation of plasminogen around fibrin threads. The clot status determines the lytic ability of enzymes; the older the clot, the less lysis. In 72 hours, the free edges Danila I. Magtira, M. Wells, R. Llamas, R. Clark, and G. L. Baum FIG. 9 . A 'Thrombolysin-treated' in-vitro clot (sampled concurrently from the same batch of preformed autologous venous clots used for embolization of a particular grehyound). A sample clot is submerged in dextrose 5% in water solution with 5,000 A(.S.D. units of Thrombolysin and left standing at room temperature for four consecutive hours. By light microscopy it is morphologicallly similar to the macroemnbolus shown in Fig. 8. H. and E. x45. of the clot are covered by endothelial cells (Back, et al., 1958) . Williams (1955) noted rapid endothelialization of artificially produced arterial clots occurring in the first 48 hours. This layer of endothelial cells has been shown to be of venous origin and to contain plasminogen activator and has been related to sites of thrombolysis (Kwaan and Astrup, 1965) . Nevertheless, this endothelial cell layer may act as a physical barrier between circulating plasmin and the fibrin clot.
Clots used in our study are 24 hours old to satisfy the first requirement for effective thrombolytic therapy. The plasminogen contents of the clots are not known quantitatively.
In the data presented, the direct continuous instillation of Thrombolysin into the main pulmonary artery, in close proximity to the macroemboli, using lower doses than those given into a systemic vein, resulted in more effective lysis of the macroemboli, probably related to the higher concentrations of enzymes reaching the clots. This probably satisfied our third requirement for effective thrombolytic therapy. Though studies of fibrinolysis and coagulation were not done, we think that accelerated lysis of pulmonary macroemboli may be achieved without significant levels of fibrinolytic activity in the systemic vessels.
The continuous instillation of thrombolytic agents into the main pulmonary artery in pulmonary thromboembolism may offer several advantages over systemic intravenous infusion. The data presented in our animals suggest that lower doses can be more effective. The method may prevent significant plasminogen activation in the plasma (where the speed of activation plays a very important role), and may prevent appreciable inhibition of clot lysis (by antiplasmin). Certainly, the importance of inhibitors (playing a central role in any thrombolytic system) and the need to measure them have been emphasized (Johnson and McCarty, 1959) and we re-emphasize this. 
